Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?

The incidence of pancreatic ductal adenocarcinoma (PDAC) has been on the rise in recent years; however, its clinical diagnosis and treatment remain challenging. Although surgical resection remains the only chance for long-term patient survival, the likelihood of initial resectability is no higher th...

Full description

Bibliographic Details
Main Authors: Chenqi Wang, Guang Tan, Jie Zhang, Bin Fan, Yunlong Chen, Dan Chen, Lili Yang, Xiang Chen, Qingzhu Duan, Feiliyan Maimaiti, Jian Du, Zhikun Lin, Jiangning Gu, Haifeng Luo
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Oncology
Subjects:
neoadjuvant chemotherapy
neoadjuvant chemoradiotherapy
borderline resectable
locally advanced
FOLFIRINOX
gemcitabin
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.828223/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.828223/full

Similar Items